Global mRNA Vaccines and Therapeutics Market Size Study, by Vaccine Type (Self-amplifying mRNA-based Vaccines, Conventional Non-amplifying mRNA-based Vaccines), by Application (Cancer, Infectious Diseases, Autoimmune Diseases, Other Applications), by Trea

Global mRNA Vaccines and Therapeutics Market Size Study, by Vaccine Type (Self-amplifying mRNA-based Vaccines, Conventional Non-amplifying mRNA-based Vaccines), by Application (Cancer, Infectious Diseases, Autoimmune Diseases, Other Applications), by Treatment Type (Monoclonal Antibody, Gene Therapy, Cell Therapy, Other Treatment Types), by End User (Research Laboratories and Organizations, Hospitals and Clinics, Other End Users) and Regional Forecasts 2022-2032

Global mRNA Vaccines and Therapeutics Market is valued at approximately USD 46.8 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.5% over the forecast period 2024-2032. Messenger ribonucleic acid (mRNA) represents a single-stranded ribonucleic acid (RNA) type crucial in the transfer of genetic information for protein production. mRNA-based therapeutics and vaccines have surfaced as groundbreaking alternatives to traditional treatment methodologies, gaining immense traction during the COVID-19 pandemic for their efficacy in addressing not only COVID-19 but also a multitude of other conditions including infectious diseases, cancer, and genetic disorders.

The rising prevalence of chronic and infectious diseases is driving significant growth in the global mRNA vaccines and therapeutics market, as these innovative treatments offer new ways to combat a range of health challenges. Chronic diseases such as cancer, cardiovascular diseases, and diabetes are becoming more common due to ageing populations and lifestyle factors. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide, highlighting the need for effective treatments. Simultaneously, infectious diseases like COVID-19 have underscored the importance of rapid vaccine development. The success of mRNA vaccines against COVID-19, such as those developed by Pfizer-BioNTech and Moderna, has demonstrated the potential of mRNA technology to quickly and effectively respond to infectious disease outbreaks. Moreover, the expansion into emerging markets, technological advancements in mRNA synthesis and manufacturing, and rising investment from both public and private sectors present various lucrative opportunities over the forecast years. However, the regulatory framework for market authorization, high production costs and infrastructure requirements are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global mRNA Vaccines and Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global mRNA Vaccines and Therapeutics Market in terms of revenue. The market growth in the region is being attributed to factors including advanced biotechnology infrastructure, significant investment in research and development, and the presence of key industry players like Moderna and Pfizer-BioNTech. The region's leadership in developing and distributing mRNA vaccines during the COVID-19 pandemic has solidified its position, with the U.S. accounting for a large share of the market. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by increasing healthcare investments, rising demand for innovative treatments, and growing awareness of the potential benefits of mRNA technology. Countries such as China, Japan, and South Korea are investing heavily in biotechnology and expanding their capabilities to develop and produce mRNA-based treatments.

Major market players included in this report are:

Pfizer Inc.

Moderna, Inc.

BioNTech SE

GlaxoSmithKline

Daiichi Sankyo

Ribometrix Inc.

Genentech

Eli Lilly and Company

Strand Therapeutics

CureVac N.V.

Arcturus Therapeutics

Translate Bio

Alnylam Pharmaceuticals

Sanofi

AstraZeneca

The detailed segments and sub-segment of the market are explained below:

By Vaccine Type:

Self-amplifying mRNA-based Vaccines

Conventional Non-amplifying mRNA-based Vaccines

By Application:

Cancer

Infectious Diseases

Autoimmune Diseases

Other Applications

By Treatment Type:

Monoclonal Antibody

Gene Therapy

Cell Therapy

Other Treatment Types

By End User:

Research Laboratories and Organizations

Hospitals and Clinics

Other End Users

By Region:

North America:

U.S.

Canada

Europe:

UK

Germany

France

Spain

Italy

ROE

Asia Pacific:

China

India

Japan

Australia

South Korea

RoAPAC

Latin America:

Brazil

Mexico

Rest of Latin America

Middle East & Africa:

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.